HYPE: Ergothioneine supplements protect brain cells and slow cognitive ageing.
But what does the evidence actually show?
Ergothioneine has credible biological mechanisms and early human research. Brain-ageing protection and dementia prevention have not been demonstrated. The larger 2025 trial did not establish a benefit on its primary memory outcome.
The hype
Ergothioneine is being promoted as a protective antioxidant for the ageing brain. The appealing argument links a compound in mushrooms, cellular defence and encouraging human biomarkers. The useful question is whether taking it leads to better cognition or slower decline in people. Those outcomes require more than a convincing mechanism.
The claim: what ergothioneine is
Ergothioneine is a sulphur-containing compound obtained from food, with mushrooms among its sources. It is studied for antioxidant and cell-protective activity, and the body has transport mechanisms that take it up and retain it. This makes human supplementation research reasonable. It does not establish that a higher blood concentration means a healthier brain. [1]
An edible mushroom, a purified compound and a mixed mushroom supplement are different exposures. Ergothioneine also differs from the particular compounds investigated in lion’s mane. A shared food category cannot transfer one intervention’s evidence to another.
What does the evidence show?
Human uptake is established more clearly than clinical brain protection. Observational studies and small trials provide signals, but the largest verified cognitive trial is more cautious than the headline suggests.
The compound reaches the blood and is retained
Cheah and colleagues gave healthy men 5 or 25 mg/day for seven days and followed blood and urine measurements afterwards. Ergothioneine concentrations increased and showed retention. Changes in assessed oxidative-damage and inflammation markers were mainly non-significant trends. The study did not test dementia prevention or long-term memory improvement.
Read the research ↗Lower levels predicted decline, but causation is unresolved
A Singapore cohort followed cognition and function in 470 older memory-clinic attendees for up to five years. Lower baseline plasma ergothioneine was associated with worse outcomes and faster decline in non-demented participants. Diet, health status and disease processes can influence the relationship. Predicting decline does not prove that raising the level with a capsule prevents it.
Read the research ↗A preliminary learning and biomarker signal
Yau and colleagues recruited 19 older adults with mild cognitive impairment. Participants received 25 mg three times weekly or placebo for one year. The report described encouraging learning-test findings and neurofilament-light-chain patterns. This very small pilot, assessed here from the published abstract, cannot establish dementia prevention, functional independence or a dependable effect across products and populations.
Read the research ↗The primary memory outcome did not improve over placebo
Zajac and colleagues studied 147 adults aged 55–79 with subjective memory complaints, using 10 or 25 mg/day for 16 weeks. Plasma levels rose substantially. The primary composite-memory analysis did not establish a treatment effect. A four-week improvement within the 25 mg group was not maintained at week 16 and was not a demonstrated advantage over placebo.
Read the research ↗Why the primary outcome matters
A primary outcome identifies the main result a trial is intended to assess. A participant group improving from its own baseline does not by itself show the supplement caused the change: repeated testing, ordinary variation and changes in the placebo group must be considered.
The 2025 paper reported selected secondary signals, including reaction-time patterns and subjective outcomes. Some appeared in analyses restricted to protocol completers. It also tested many domains, reported protocol amendments and was funded by the ingredient supplier, with one author employed there. Those details call for replication; they are not reasons to dismiss the trial automatically. [4]
Blood levels and biomarkers are not dementia prevention
Higher plasma ergothioneine shows exposure. Neurofilament light chain is a marker related to neuronal injury, not a direct measurement of preserved independence or prevented dementia. Similarly, an isolated telomere observation cannot demonstrate longer lifespan. The steps between a marker, a cognitive test and a meaningful clinical outcome must remain visible.
Neither cognitive trial demonstrated fewer new dementia diagnoses. Calling the supplement a brain-ageing protector therefore extends beyond the outcomes actually tested. This is our interpretation of the trial designs, not proof that a future well-designed trial could never show benefit. [3] [4]
The catch: population, dose and duration
Subjective memory complaints and diagnosed mild cognitive impairment are different starting points. The larger trial’s participants had broadly normal cognition and relatively high baseline ergothioneine. That may influence the opportunity to improve, but a negative main result cannot be converted into proof of benefit in people with lower levels.
Ten or 25 mg daily and 25 mg three times weekly are different study schedules. They are not validated anti-ageing prescriptions. The short trial and tiny year-long pilot did not reveal a clear safety signal in the measured outcomes, but cannot establish all long-term risks, interactions or commercial-product quality. [3] [4]
What this means for you
There is no strong basis for buying ergothioneine with the expectation that it prevents dementia or slows brain ageing. Eating mushrooms as part of a diet is a food choice; it should not be sold as a clinically established equivalent to brain-protective treatment.
If memory changes are persistent or worsening, seek an assessment of the cause. A supplement should not delay that process. Follow the research for larger independent trials with prespecified cognitive and functional outcomes, sufficient follow-up and clear comparisons against placebo.
For another compound with a different mechanism and trial history, read the spermidine and brain-ageing investigation. Similar promises do not mean identical evidence.
Interesting biology and preliminary signals. Protection against human brain ageing and dementia remains unproven.
Research & Sources
1. Cheah et al. (2017). Administration of Pure Ergothioneine to Healthy Human Subjects: Uptake, Metabolism, and Effects on Biomarkers of Oxidative Damage and Inflammation. Antioxidants & Redox Signaling.
Read the original source ↗2. Low Plasma Ergothioneine Predicts Cognitive and Functional Decline in an Elderly Cohort Attending Memory Clinics (2022). Antioxidants.
Read the original source ↗3. Yau et al. (online 2024). Investigating the efficacy of ergothioneine to delay cognitive decline in mild cognitively impaired subjects: A pilot study. Journal of Alzheimer’s Disease. Published abstract assessed.
Read the original source ↗4. Zajac et al. (2025). The Effect of Ergothioneine Supplementation on Cognitive Function, Memory, and Sleep in Older Adults with Subjective Memory Complaints: A Randomized Placebo-Controlled Trial. Nutraceuticals.
Read the original source ↗Evidence reviewed: October 2026
This targeted editorial review assessed research available on 13 October 2026; it is not an exhaustive systematic review. Sources were checked against published research records and full text where accessible. Abstract-only assessments are identified. Evidence vs Hype provides education, not individual diagnosis or treatment. Featured artwork is conceptual, not a study result. No commercial product was selected or endorsed for this investigation.